Comparing treatments for relapsed or hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of leukemia called non-APL AML (not the APL subtype).
- Your leukemia has come back for the first or second time, or did not respond to earlier treatment.
- Your doctor thinks you could be treated with either a low-intensity or high-intensity chemotherapy approach.
- Both types of treatment are available at your local hospital.
- You are older than 18 years.
- You are not pregnant or breastfeeding, and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This Phase 2 trial tests a new combination treatment (the “CAV regimen”) for people with relapsed or refractory acute myeloid leukemia (AML). It may help your body control leukemia again, especially if prior standard intensive treatments were not enough or the leukemia came back.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
This trial uses a special lab test (pharmacoscopy) to help your doctor choose the best standard chemotherapy for your AML. It is for people whose leukemia has returned or not responded to treatment, and who are strong enough for intensive chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.